148 related articles for article (PubMed ID: 29769617)
1. A new method of identifying glioblastoma subtypes and creation of corresponding animal models.
Zhou X; Li G; An S; Li WX; Yang H; Guo Y; Dai Z; Dai S; Zheng J; Huang J; Iavarone A; Zhao X
Oncogene; 2018 Aug; 37(35):4781-4791. PubMed ID: 29769617
[TBL] [Abstract][Full Text] [Related]
2. Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets.
Ghimenti C; Fiano V; Chiadò-Piat L; Chiò A; Cavalla P; Schiffer D
J Neurooncol; 2003 Jan; 61(2):95-102. PubMed ID: 12622447
[TBL] [Abstract][Full Text] [Related]
3. Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.
Hinrichs BH; Newman S; Appin CL; Dunn W; Cooper L; Pauly R; Kowalski J; Rossi MR; Brat DJ
Acta Neuropathol Commun; 2016 Jan; 4():4. PubMed ID: 26757882
[TBL] [Abstract][Full Text] [Related]
4. CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry.
Purkait S; Jha P; Sharma MC; Suri V; Sharma M; Kale SS; Sarkar C
Neuropathology; 2013 Aug; 33(4):405-12. PubMed ID: 23311918
[TBL] [Abstract][Full Text] [Related]
5. Age-dependent prognostic effects of genetic alterations in glioblastoma.
Batchelor TT; Betensky RA; Esposito JM; Pham LD; Dorfman MV; Piscatelli N; Jhung S; Rhee D; Louis DN
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):228-33. PubMed ID: 14734474
[TBL] [Abstract][Full Text] [Related]
6. Detection and Correlation of Single and Concomitant
Pessôa IA; Amorim CK; Ferreira WAS; Sagica F; Brito JR; Othman M; Meyer B; Liehr T; de Oliveira EHC
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151164
[TBL] [Abstract][Full Text] [Related]
7. TP53 gain-of-function mutation promotes inflammation in glioblastoma.
Ham SW; Jeon HY; Jin X; Kim EJ; Kim JK; Shin YJ; Lee Y; Kim SH; Lee SY; Seo S; Park MG; Kim HM; Nam DH; Kim H
Cell Death Differ; 2019 Mar; 26(3):409-425. PubMed ID: 29786075
[TBL] [Abstract][Full Text] [Related]
8. TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma.
Heaton CM; Durr ML; Tetsu O; van Zante A; Wang SJ
Laryngoscope; 2014 Jul; 124(7):E267-73. PubMed ID: 24431303
[TBL] [Abstract][Full Text] [Related]
9. Genetic analyses for predictors of radiation response in glioblastoma.
Shih HA; Betensky RA; Dorfman MV; Louis DN; Loeffler JS; Batchelor TT
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):704-10. PubMed ID: 15978739
[TBL] [Abstract][Full Text] [Related]
10. Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme.
Kraus JA; Glesmann N; Beck M; Krex D; Klockgether T; Schackert G; Schlegel U
J Neurooncol; 2000 Jun; 48(2):89-94. PubMed ID: 11083071
[TBL] [Abstract][Full Text] [Related]
11. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
Biernat W; Debiec-Rychter M; Liberski PP
Pol J Pathol; 1998; 49(4):267-71. PubMed ID: 10323080
[TBL] [Abstract][Full Text] [Related]
12. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
[TBL] [Abstract][Full Text] [Related]
13. Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1.
Suwala AK; Stichel D; Schrimpf D; Maas SLN; Sill M; Dohmen H; Banan R; Reinhardt A; Sievers P; Hinz F; Blattner-Johnson M; Hartmann C; Schweizer L; Boldt HB; Kristensen BW; Schittenhelm J; Wood MD; Chotard G; Bjergvig R; Das A; Tabori U; Hasselblatt M; Korshunov A; Abdullaev Z; Quezado M; Aldape K; Harter PN; Snuderl M; Hench J; Frank S; Acker T; Brandner S; Winkler F; Wesseling P; Pfister SM; Reuss DE; Wick W; von Deimling A; Jones DTW; Sahm F
Acta Neuropathol; 2021 Jul; 142(1):179-189. PubMed ID: 33876327
[TBL] [Abstract][Full Text] [Related]
14. A recombinant lentiviral PDGF-driven mouse model of proneural glioblastoma.
Rahme GJ; Luikart BW; Cheng C; Israel MA
Neuro Oncol; 2018 Feb; 20(3):332-342. PubMed ID: 29016807
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
16. Molecular and Genomic Alterations in Glioblastoma Multiforme.
Crespo I; Vital AL; Gonzalez-Tablas M; Patino Mdel C; Otero A; Lopes MC; de Oliveira C; Domingues P; Orfao A; Tabernero MD
Am J Pathol; 2015 Jul; 185(7):1820-33. PubMed ID: 25976245
[TBL] [Abstract][Full Text] [Related]
17. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations.
Zaki MM; Mashouf LA; Woodward E; Langat P; Gupta S; Dunn IF; Wen PY; Nahed BV; Bi WL
Sci Rep; 2021 Sep; 11(1):18009. PubMed ID: 34504233
[TBL] [Abstract][Full Text] [Related]
18. Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL.
Cobbers JM; Wolter M; Reifenberger J; Ring GU; Jessen F; An HX; Niederacher D; Schmidt EE; Ichimura K; Floeth F; Kirsch L; Borchard F; Louis DN; Collins VP; Reifenberger G
Brain Pathol; 1998 Apr; 8(2):263-76. PubMed ID: 9546285
[TBL] [Abstract][Full Text] [Related]
19. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group.
Lerman DM; Monument MJ; McIlvaine E; Liu XQ; Huang D; Monovich L; Beeler N; Gorlick RG; Marina NM; Womer RB; Bridge JA; Krailo MD; Randall RL; Lessnick SL;
Pediatr Blood Cancer; 2015 May; 62(5):759-65. PubMed ID: 25464386
[TBL] [Abstract][Full Text] [Related]
20. Ionizing radiation-induced gene expression changes in TP53 proficient and deficient glioblastoma cell lines.
Godoy PR; Mello SS; Magalhães DA; Donaires FS; Nicolucci P; Donadi EA; Passos GA; Sakamoto-Hojo ET
Mutat Res; 2013 Aug; 756(1-2):46-55. PubMed ID: 23817105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
